Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.

abstract：:The patient granulocyte-colony stimulating factor (G-CSF) response is represented by the leukocyte peak in the blood induced by a single dose of G-CSF after chemotherapy, and is correlated with subsequent neutropenic infection risk. General patterns for a meaningful risk group stratification, have not yet been determi...

journal_title：Leukemia & lymphoma

authors： Straka C,Salwender H,Schnabel B,Sandherr M,Wandt H,Hübel K,Scheid C,Metzner B,Hentrich M,Franke D,Weidenegger G,Freund M,Sezer O,Einsele H,Hinke A,Emmerich B

更新日期：2015-02-01 00:00:00

abstract：:Adolescents and adults with acute lymphoblastic leukemia/lymphoma (ALL) have better outcomes when treated using pediatric protocols compared with treatment using adult protocols. We reviewed the progress and outcomes of 40 adolescents and adults up to 45 years of age, from three Australian centers, treated on the inte...

journal_title：Leukemia & lymphoma

authors： Hocking J,Schwarer AP,Gasiorowski R,Patil S,Avery S,Gibson J,Iland H,Ho PJ,Joshua D,Muirhead J,Lai H,Irving I

更新日期：2014-12-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:The approval of venetoclax, a 'BH3-mimetic' antagonist of the BCL-2 anti-apoptotic protein, for chronic lymphocytic leukemia represents a major milestone in translational apoptosis research. Venetoclax has already received 'breakthrough' designation for acute myeloid leukemia, and is being studied in many other tumor ...

journal_title：Leukemia & lymphoma

authors： Bose P,Gandhi V,Konopleva M

更新日期：2017-09-01 00:00:00

abstract：:A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

journal_title：Leukemia & lymphoma

authors： Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

更新日期：2007-07-01 00:00:00

abstract：:Four patients less than 20 years of age with Hodgkin's disease, who had developed either second or third relapse, were treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT). Peripheral blood stem cells (PBSC) were collected after the administration of high-dose cytosine ara...

journal_title：Leukemia & lymphoma

authors： Matsuzaki A,Okamura J,Nagatoshi Y,Kai T,Ohga S,Gondo H,Inaba S,Ueda K

更新日期：1995-08-01 00:00:00

abstract：:Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

journal_title：Leukemia & lymphoma

authors： Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

更新日期：2019-03-01 00:00:00

abstract：:Allogeneic stem cell transplantation (SCT) represents a curative treatment option for patients with leukemia and lymphoma. T lymphocytes contained in the allograft mediate a graft-versus-leukemia (GVL) effect and prevent graft rejection; however, T cells also initiate graft-versus-host disease (GVHD). Identification o...

journal_title：Leukemia & lymphoma

authors： Fowler DH,Gress RE

更新日期：2000-07-01 00:00:00

abstract：:Bryostatin, a macrocyclic lactone and protein kinase C (PKC) modulator, has been shown to have differentiation and anti-tumor activity against several leukemia cell lines in vitro. In this study, we demonstrated Bryostatin-induced differentiation in B-cell chronic lymphocytic leukemia (B-CLL) cells, characterized by a...

journal_title：Leukemia & lymphoma

authors： Thomas A,Pepper C,Hoy T,Bentley P

更新日期：2004-05-01 00:00:00

abstract：:Several clinical and cell biological features, such as sex, age, leukemic cell burden, morphologic FAB type, and immunophenotype, have prognostic value in childhood acute lymphoblastic leukemia (ALL). The explanation for their prognostic significance is unclear, but might be related to cellular drug resistance. We pro...

journal_title：Leukemia & lymphoma

authors： Kaspers GJ,Pieters R,Van Zantwijk CH,Van Wering ER,Veerman AJ

更新日期：1995-11-01 00:00:00

abstract：:In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

journal_title：Leukemia & lymphoma

authors： Orpana A,Salven P

更新日期：2002-02-01 00:00:00

abstract：:We evaluated patients with newly diagnosed ALL treated at the Cleveland Clinic during the years 1996 through 2005. Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival. On univariate analysis, significant pro...

journal_title：Leukemia & lymphoma

authors： Advani AS,Jin T,Ramsingh G,Tiu R,Saber W,Theil K,Sobecks R,Sekeres M,Copelan E,Sungren S,Tripp B,Kalaycio M

更新日期：2008-08-01 00:00:00

abstract：:Gain-of-function EZH2 mutation promotes H3K27 trimethylation (H3K27me3) and lymphoid transformation of germinal center (GC) derived B-cell lymphoma, such as GCB diffuse large B-cell lymphoma (DLBCL), but not activated B-cell (ABC) DLBCL. It is unclear whether expression levels of EZH2 and consequential H3K27me3 vary b...

journal_title：Leukemia & lymphoma

authors： Zhou Z,Gao J,Popovic R,Wolniak K,Parimi V,Winter JN,Licht JD,Chen YH

更新日期：2015-01-01 00:00:00

abstract：:Although BCR-ABL is the hallmark genetic abnormality of chronic myeloid leukemia (CML), secondary molecular events responsible for the evolution of the disease to blast crisis are yet to be deciphered. Taking into account the significant association of ecotropic viral integration site I (EVI1) in CML drug resistance, ...

journal_title：Leukemia & lymphoma

authors： Kuila N,Nayak KB,Halder A,Agatheeswaran S,Biswas G,Biswas S,Pattnayak NC,Chakraborty S

更新日期：2017-08-01 00:00:00

abstract：:Current understanding of molecular genetics enables the establishment of new categories based on pathogenesis. Philadelphia (Ph) chromosome-positive leukemia has been reclassified into two molecularly distinct subsets, and the leukemogenesis at the cell level might be linked to the molecular changes. Therefore, treatm...

journal_title：Leukemia & lymphoma

authors： Ohyashiki K,Ohyashiki JH,Toyama K

更新日期：1993-01-01 00:00:00

abstract：:Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were...

journal_title：Leukemia & lymphoma

authors： Dong LH,Zhang LJ,Wang WJ,Lei W,Sun X,Du JW,Gao X,Li GP,Li YF

更新日期：2016-07-01 00:00:00

abstract：:The blast cells from up to 70% of patients with acute myeloblastic leukaemia exhibit a variable degree of autonomous growth in vitro, which is related to the production of autocrine growth factors. It has recently been established that patients with autonomous blast cell growth have both a lower remission rate and a h...

journal_title：Leukemia & lymphoma

authors： Russell NH,Hunter AE,Bradbury D,Zhu YM,Keith F

更新日期：1995-01-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00

abstract：:A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...

journal_title：Leukemia & lymphoma

authors： Quitt M,Bazac I,Gross B,Aghai E

更新日期：1994-11-01 00:00:00

abstract：:Multiple myeloma (MM) is an essentially incurable malignancy associated with profound immune dysregulation. Despite the advent of novel therapies and improvements in survival over the last 10 years, death from progressive disease and infection remains a common outcome. Natural killer (NK) cells are CD56(+)CD3(-) large...

journal_title：Leukemia & lymphoma

authors： Godfrey J,Benson DM Jr

更新日期：2012-09-01 00:00:00

abstract：:Treatment results of 47 pregnant women with Hodgkin's disease (HD) are analyzed using data reported in the literature since 1960. Twenty-three of the patients were treated with radiation during pregnancy and 17 of the 23 patients (74%) were reported to be long term disease-free survivors. All of these pregnancies resu...

journal_title：Leukemia & lymphoma

authors： Yahalom J

更新日期：1990-01-01 00:00:00

abstract：:The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

journal_title：Leukemia & lymphoma

authors： Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

更新日期：2013-12-01 00:00:00

abstract：:Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome in a consecutive cohort of 175 patients with aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or Burkitt's lymphoma was encountered. All these patients had obtained a complete remission with ...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Magagnoli M,Frezza G,Prologo G,Gherlinzoni F,Bendandi M,Albertini P,Babini L,D'Alessandro R,Tura S

更新日期：1999-02-01 00:00:00

abstract：:Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

journal_title：Leukemia & lymphoma

authors： Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

更新日期：2007-01-01 00:00:00

abstract：:The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

journal_title：Leukemia & lymphoma

authors： van Besien K

更新日期：2014-08-01 00:00:00

abstract：:This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from...

journal_title：Leukemia & lymphoma

authors： Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

更新日期：1999-10-01 00:00:00

abstract：:Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were divided into three...

journal_title：Leukemia & lymphoma

authors： Modi D,Kim S,Singh V,Ayash L,Alavi A,Ratanatharathorn V,Uberti JP,Deol A

更新日期：2019-11-01 00:00:00

abstract：:Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...

journal_title：Leukemia & lymphoma

authors： Ciolli S,Vannucchi AM,Leoni F,Nozzoli C,Longo G,Salati A,Pancrazzi A,Bianchi L,Gigli F,Bosi A

更新日期：2004-01-01 00:00:00

abstract：:A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening ...

journal_title：Leukemia & lymphoma

authors： Kaeda J,Ringel F,Oberender C,Mills K,Quintarelli C,Pane F,Koschmieder S,Slany R,Schwarzer R,Saglio G,Hemmati P,van Lessen A,Amini L,Gresse M,Vagge E,Burmeister T,Serra A,Carson A,Schwarz M,Westermann J,Jundt F,D

更新日期：2015-07-01 00:00:00

abstract：:Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, although the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemothe...

journal_title：Leukemia & lymphoma

authors： Krull KR,Hockenberry MJ,Miketova P,Carey M,Moore IM

更新日期：2013-03-01 00:00:00